A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

drug protocol number
D8221C00001
drug sponsor
Acerta Pharma BV (one of AstraZeneca AB group of companies)
drug study
Acalabrutinib
drug trial site
KFSH
drug status
Ongoing
drug phase